drug allergy: principles and updates
Upload: chulalongkorn-allergy-and-clinical-immunology-research-group
Post on 12-Jul-2015
1.308 views
TRANSCRIPT
![Page 1: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/1.jpg)
Reviewed by
Wat Mitthamsiri, MD
![Page 2: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/2.jpg)
• Definitions
• Effects to human health
• Classifications of adverse drug reactions
• Chronological classification
• Clinical classification
• Mechanisms of drug allergy
• General approach
• Future of drug allergy prediction
• Future of drug allergy diagnosis
• Conclusion
Outline
![Page 3: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/3.jpg)
![Page 4: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/4.jpg)
Adverse Event (AE)
= Medical occurrence temporally associated with the use of a medicinal product, but not necessarily causally related.
Definitions
Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Sweden, glossary, http://www.who-umc.org/graphics/8321.pdf, p. 1.
![Page 5: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/5.jpg)
Adverse Event (AE)
= Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related.
Any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.
Can arise from any use of the drug (e.g., off-label use, use in combination with another drug) and from any route of administration, formulation, or dose, including an overdose.
Definitions
US FDA, 2013, Good Review Practice: Clinical Review of Investigational New Drug Applications
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 079753.pdf
![Page 6: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/6.jpg)
Adverse Reaction (AR)
=A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function
Definitions
Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Sweden, glossary, http://www.who -umc.org/graphics/8321.pdf, p. 1.
![Page 7: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/7.jpg)
Adverse Reaction (AR)
= An undesirable effect, reasonably associated with use of a drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence.
Not include all adverse events, only those for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event.
Definitions
US FDA, 2013, Good Review Practice: Clinical Review of Investigational New Drug Applications
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 079753.pdf
![Page 8: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/8.jpg)
• Type A—Exaggerated pharmacological response • Pharmacodynamic (e.g., bronchospasm from beta-blockers)
• Toxic (e.g., deafness from aminoglycoside overdose)
• Type B—Nonpharmacological, often allergic, response • Medicine-induced diseases (e.g., antibiotic-associated colitis)
• Allergic reactions (e.g., penicillin anaphylaxis)
• Idiosyncratic reactions (e.g., aplastic anemia with chloramphenicol)
• Type C—Continuous or long term (time related) • Osteoporosis with oral steroids
Classification of adverse drug reaction
World Health Organization. 2007. Drug and Therapeutics Committee Training Course. Session 4. Assessing and Managing Medicine Safety
![Page 9: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/9.jpg)
• Type D—Delayed (lag time)
• Teratogenic effects with anticonvulsants or lisinopril
• Type E—Ending of use (withdrawal)
• Withdrawal syndrome with benzodiazepines
• Type F—Failure of efficacy (no response)
• Resistance to antimicrobials
Classification of adverse drug reaction
World Health Organization. 2007. Drug and Therapeutics Committee Training Course. Session 4. Assessing and Managing Medicine Safety
![Page 10: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/10.jpg)
Classification of adverse drug reaction
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 11: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/11.jpg)
Drug hypersensitivity reactions (DHRs)
= Adverse effects of pharmaceutical formulations (including active drugs and excipients) that clinically resemble allergy
Drug allergy
= DHRs for which a definite immunological mechanism (either drug-specific antibody or T cell) is demonstrated.
Drug allergy
= Drug reactions resulting from consequences of a drug-specific immune response
Definition
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Gomes ER, Demoly P., Curr Opin Allergy Clin Immunol 2005;5:309-16.
![Page 12: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/12.jpg)
![Page 13: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/13.jpg)
• IPD: 10-20% of patients
• OPD: 25% of patients
• Type A reactions : About 85-90% of all ADRs.
• Type B reactions : About 10-15% of all ADRs.
• Immune-mediated (drug allergy) : About 6-10% of ADRs.
Epidemiology
Gomes ER, Demoly P., Curr Opin Allergy Clin Immunol 2005;5:309-16.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 14: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/14.jpg)
• Most common drug groups causing hypersensitivity reactions
• β-lactam antibiotics
• Nonsteroidal antiinflammatory drugs (NSAIDs)
• Cutaneous reactions are most common clinical manifestations, but SJS/TEN and DIHS/DRESS are rare
• Mortality rate: In USA, about 1 of every 300 hospitalized patients (amounting to 106,000 estimated deaths in 1994)
Epidemiology
Gomes ER, Demoly P., Curr Opin Allergy Clin Immunol 2005;5:309-16.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 15: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/15.jpg)
• Immune-mediated drug hypersensitivity
• Accounts for 6-10% of the adverse drug reactions
• Rank 5th leading causes of death in the US.
• With <10% of all adverse drug reactions reported, the magnitude of the problem is significant
• Estimates of costs >$US30 billion annually in the US (1995 value)
• Hypersensitivity: The leading reason for taking drugs off the market, so the costs of not determining the potential of a drug to produce hypersensitivity in the pre-clinical phase of drug development can be substantial.
Epidemiology
Ratajczak HV, Toxicol Rev. 2004;23(4):265-80.
![Page 16: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/16.jpg)
• The WHO International Drug Monitoring Programme
• Started in 1968
• Main objectives: To identify the earliest possible pharmacovigilance signals
• Currently 120 official member countries from all parts of the world contributing individual case safety reports (ICSRs) to the WHO Global ICSR Database System, VigiBase.
• Thailand is one of an official members since 1984
Epidemiology: Global scale monitoring
M. Lindquist, Drug Information Journal, Vol. 42, pp. 409–419, 2008 • 0092-8615/2008
http://www.who-umc.org/DynPage.aspx?id=98080&mn1=7347&mn2=7252&mn3=7322&mn4=7324
![Page 17: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/17.jpg)
• VigiBase
• Maintained and developed on behalf of WHO by the Uppsala Monitoring Centre (UMC), situated in Uppsala, Sweden.
• A web-based reporting tool
• An automated signal detection process using advanced data mining
• Search facilities, available to the official staff of national centers of member countries and, on request, to other stakeholders.
Epidemiology: Global scale monitoring
M. Lindquist, Drug Information Journal, Vol. 42, pp. 409–419, 2008 • 0092-8615/2008
http://www.who-umc.org/DynPage.aspx?id=98080&mn1=7347&mn2=7252&mn3=7322&mn4=7324
![Page 18: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/18.jpg)
Epidemiology: Global scale monitoring
M. Lindquist, Drug Information Journal, Vol. 42, pp. 409–419, 2008 • 0092-8615/2008
![Page 19: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/19.jpg)
Epidemiology: Global scale monitoring
http://www.who-umc.org/graphics/28351.gif
![Page 20: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/20.jpg)
Epidemiology
https://open.fda.gov/drug/event/
![Page 21: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/21.jpg)
Epidemiology
Health Product Vigilance Center (HPVC), กองแผนงานและวชิาการ อย., Spontaneous Reports of Adverse Drug Reaction 2012
http://thaihpvc.fda.moph.go.th/thaihvc/Public/Webpage/main.jsf
![Page 22: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/22.jpg)
Epidemiology
Health Product Vigilance Center (HPVC), กองแผนงานและวชิาการ อย., Spontaneous Reports of Adverse Drug Reaction 2012
http://thaihpvc.fda.moph.go.th/thaihvc/Public/Webpage/main.jsf
![Page 23: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/23.jpg)
![Page 24: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/24.jpg)
Chronological classification
Gomes ER, Demoly P., Curr Opin Allergy Clin Immunol 2005;5:309-16.
![Page 25: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/25.jpg)
Clinical classification
Bircher A. and Scherer K. Med Clin N Am 94 (2010) 711–725
![Page 26: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/26.jpg)
![Page 27: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/27.jpg)
Agents Immune system
Effector functions
General concept of immune response
![Page 28: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/28.jpg)
Agents Immune system
Effector functions
General concept of immune response
![Page 29: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/29.jpg)
Agents Immune system
Effector functions
General concept of immune response
???
![Page 30: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/30.jpg)
![Page 31: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/31.jpg)
• Innate immune recognition
• Danger hypothesis
• Evidence: contact sensitizers can cause upregulation of costimulatory molecules such as CD86 or CD40 and phosphorylation of signaling molecules in dendritic cells exposed in vitro
• The data are less clear for drugs causing systemic reactions.
• Adaptive immune recognition
• Discussed later
Can drug be antigen?
Coulter EM, et al. J Pharmacol Exp Ther 2007;320:885-92.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 32: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/32.jpg)
Can drug be antigen?
AK Abbas., et al. Cellular and Molecular Immunology 7th edition, 2012,109-138
8-11 peptide rersidues 10-30 peptide rersidues
![Page 33: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/33.jpg)
Can drug be antigen?
AK Abbas., et al. Cellular and Molecular Immunology 7th edition, 2012,139-172
B cell receptor complex T cell receptor complex
![Page 34: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/34.jpg)
Can drug be antigen?
Image from: AK Abbas., et al. Cellular and Molecular Immunology 7th edition, 2012,89-108
With few exceptions, an antigen must be presented to the immune system in multivalent form to elicit a specific immune response (i.e., sensitization) and to activate immunopathologic mechanisms.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 35: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/35.jpg)
• Being complete allergen by itself
• Foreign macromolecules
• Insulin and other hormones
• Enzymes and protamine
• Antisera
• Recombinant proteins
• Vaccines
• Functionally multivalent chemical
• Succinylcholine
• Other quaternary ammonium compounds
How can drug get its antigenicity?
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 36: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/36.jpg)
• Direct haptenation
• β-Lactam antibiotics
• Quinidine
• Cis-platinum
• Penicillamine
• Barbiturates
• Antithyroid drugs
• Heavy metals (gold)
Drug antigenicity
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 37: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/37.jpg)
• Metabolism to haptenic form
• Sulfonamides*
• Acetaminophen†
• Phenacetin*
• Phenytoin‡
• Procainamide*
• Halothane§
• *Postulated intermediate: hydroxylamine.
• †Postulated intermediate: quinone imine.
• ‡Postulated intermediate: arene oxide.
• §Postulated intermediates: radicals, acylhalides.
Drug antigenicity
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 38: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/38.jpg)
Drug antigenicity
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 39: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/39.jpg)
Factors involve drug haptens antigenicity
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Genetic factors
• Haptenation (MHC presentation or augmentation of response)
• Acetylator phenotype
• Metabolic factors
• Rate of haptenation
• Hapten inhibition
• Dehaptenation
• Glutathione levels
• Preformed multivalent drug forms
![Page 40: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/40.jpg)
Factors involve drug haptens antigenicity
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Adjuvants
• Benzathine penicillin
• Oil-emulsified penicillins,
• Occult exposure to native or cross-reactive epitopes
• Quaternary ammonium epitope in muscle relaxant drugs is widely distributed in a variety of foods and cosmetics
• Concomitant infections
• High rate of putatively immunologic dermatologic reactions to sulfonamides and other drugs in patients infected with HIV
![Page 41: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/41.jpg)
P-i concepts
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
1, The drug fits into some TCR with sufficient affinity to cause a signal. 2, This drug-TCR interaction is supplemented by a MHC interaction T cells react and proliferate. No metabolism of drugs required. The reactive T cell is probably preactivated and has an additional peptide specificity. Alternatively, the drug binds first to the HLA molecule, and the new drug-HLA complex stimulates T cells
![Page 42: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/42.jpg)
P-i concepts
Schaerli P, et al. J Exp Med 2004; 199:1265-75.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• It can explain “bizarre features” of drug hypersensitivity
• Rapid flow of symptoms at the first encounter with the drug, notably without a sensitization phase
• Drug hypersensitivity in patient with condition that lower T cell reactivity threshold
• During some generalized viral infections: EBV, CMV, HHV6, HIV
• During exacerbations of autoimmune diseases
• Preferential involvement of the skin in drug allergy.
• Skin is a repository for an enormous number of T cells, many of which are effector memory T cells that react rapidly if immunogenic agents penetrate the skin barrier.
![Page 43: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/43.jpg)
![Page 44: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/44.jpg)
Modified Gell and Coombs classification
Pichler et al., Med Clin N Am 94 (2010) 645–664
![Page 45: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/45.jpg)
“Idiosyncratic mechanism”
![Page 46: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/46.jpg)
Differences from immunologic form
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 47: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/47.jpg)
Shock after radiocontrast media • Iodine sensitivity?
![Page 48: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/48.jpg)
Shock after radiocontrast media • Iodine sensitivity?
• Contrast media reactors tolerate iodine-containing surgical scrubs, and vice versa
• Its hypertonicity augments basophil and mast cell histamine release
• Some nonionic contrast agents’ reaction may be IgE mediated
Schabelman E, Witting M. J Emerg Med 2010;39: 701-7.
Stellato C, et al. J Allergy Clin Immunol 1996;97:838-50.
Stellato C, Adkinson NF Jr., Allergy 1998; 53:1111-3.
![Page 49: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/49.jpg)
Risk factors for contrast media reactions
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Atopic background (relative risk: 3 to 5)
• Female gender
• Underlying severe cardiovascular disease
• History of radiocontrast reactions
• History of drug allergy in general
Stellato C, et al. J Allergy Clin Immunol 1996;97:838-50.
Stellato C, Adkinson NF Jr., Allergy 1998; 53:1111-3.
![Page 50: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/50.jpg)
Prevention: premedication
Tramèr MR, et al., BMJ 2006;333:675.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 51: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/51.jpg)
ASA and NSAIDs
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Aspirin-induce acute bronchospasm/rhinosinusitis = AERD.
• Other NSAIDs, except COX-2 inhibitors, exhibit virtually complete cross-reactivity in this syndrome
• Common functional property of COX inhibition (especially COX-1) is involved in the pathogenesis
• ASA-induced urticarial reactions (most common)
• In patients with U/D chronic urticaria: Found 30%
• Cross-reactivity among COX-1 inhibitors is very likely
• In patients without U/D chronic urticaria
• Cross-reactivity with other NSAIDs is less likely
![Page 52: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/52.jpg)
Taxanes
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Taxanes can lead to mast cell degranulation by nonimmune mechanisms
• Commonly occur with the first infusion
• Slowing the infusion and pretreatment with corticosteroids and antihistamines can prevent hypersensitivity reactions in most cases.
![Page 53: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/53.jpg)
Hemolytic anemia
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Hemolytic anemia can be immunologic: penicillins
• And also idiosyncratic: primaquine-sensitive anemia
• G6PD deficiency renders erythrocytes sensitive to the metabolic consequences of drugs with antioxidant properties
• Clinical phenotype is similar to immune hemolysis except for the absence of drug antibodies
Dern RJ, Beutler E, Alving AS. J Lab Clin Med 1981;97:750-9.
![Page 54: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/54.jpg)
Local Anesthetics
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Vasovagal syncope (mimic anaphylaxis)
• Paresthesias and lightheadedness
• Pharmacologic toxicity
• Symptoms are more common in drug-intolerant patients
• Episodes of anxiety or panic associated with a procedure
• Rare IgE responses
• Rare antibody-mediated reactions
![Page 55: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/55.jpg)
Flushing during vancomycin infusion
Wallace MR, et al., J Infect Dis. 1991 Dec;164(6):1180-5.
Dormis MJ, Moritz ML, Front Pediatr. 2014 Jun 5;2:55.
Red man syndrome (RMS)
• Most common toxicity of intravenous vancomycin therapy
• Associated with rapid infusion of large doses of vancomycin
• Occurs secondary to histamine release from mast cells
• Manifestations
• Generalized flushing
• Pruritus
• Erythematous rash
• Chest pain
• Dyspnea
• Hypotension
![Page 56: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/56.jpg)
Biological agents
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Adverse reactions at the first exposure are not uncommon with biological agents and reflect a variety of mechanisms
• Acute induction or release of cytokines
• Protein infusion reactions
• Secondary toxicities of the product
• Carbohydrate epitopes such as α-galactose added by bacteria during recombinant synthesis are the object of IgE-dependent reactions
![Page 57: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/57.jpg)
Recognize the risk factors
![Page 58: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/58.jpg)
Drug-related factors
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Polymerization or macromolecular contamination
• Multivalency of drug epitopes -> risk of IgE-mediated reaction
• Protein reactivity
• Cross-reactive epitopes
• Impurity of the preparation (e.g., containing acetylsalicylic acid-anhydride in acetylsalicylic acid)
• Concomitant medications (e.g., allopurinol, amoxicillin)
![Page 59: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/59.jpg)
Patient’s disease
K Scherer, AJ Bircher, Med Clin N Am 94 (2010) 681–689
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Need for prolonged or repeated courses of therapy (e.g., cystic fibrosis, chronic sinusitis, immunodeficiencies)
• Dose and duration of therapy
• Frequency of drug treatment
• Route of administration
• Immunogenicity: High Low
• Concomitant diseases (e.g., EBV infections and amoxicillin; AIDS and sulfonamides)
Topical SC IM Oral IV
![Page 60: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/60.jpg)
Patient’s individual
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Prior reaction history (both related and unrelated drugs)
• Family history of drug allergy
• Prior unrecognized exposure eg.in-utero/in breast milk drug exposure of fetus
• Atopy (IgE-mediated reactions)
• Multiple drug allergy syndromes
• Persistence of drug-specific immune response
• Female sex in certain reactions (gemifloxacin rash)
• HLA class I (B and A) allele
![Page 61: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/61.jpg)
Establishing diagnosis
![Page 62: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/62.jpg)
Gathering information
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Assemble clinical data set.
• Complete drug reaction history
• Atopic history
• List of concomitant medications, with chart of starts, stops, and dose changes
• Previous exposures to same or cross-reacting drugs
• Chronology of all drug reactions: attributable signs and symptoms, useful nonspecific laboratory tests (e.g., eosinophilia, ESR, tryptase, proteinuria)
• Clinical syndrome diagnosis
• Detect danger signs and internal organs involvement
![Page 63: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/63.jpg)
Danger sign
K Scherer, AJ Bircher, Med Clin N Am 94 (2010) 681–689
For severe immediate-type reactions
• Sudden onset of extensive pruritus, in particular palmoplantar and scalp
• Flush on face and neck with conjunctivitis and rhinitis
• Angioedema of the oral mucosa, in particular pharynx and larynx
• Severe urticaria
• Dyspnea and bronchospasm, especially in known asthmatics
• Hypotension
![Page 64: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/64.jpg)
Danger sign
K Scherer, AJ Bircher, Med Clin N Am 94 (2010) 681–689
For severe delayed-type reactions
• Centrofacial edema (diffuse erythematous swelling)
• Involvement of large body surfaces or erythroderma
• Painful skin, skin tender to touch
• Atypical target lesions
• Nikolsky sign positive, vesiculobullous lesions, epidermolysis
• Erosive stomatitis; mucositis, especially if affecting more than one mucosa
• Hemorrhagic necrotizing lesions
• Purpura
![Page 65: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/65.jpg)
Danger sign
Gomes ER, Demoly P., Curr Opin Allergy Clin Immunol 2005;5:309-16.
![Page 66: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/66.jpg)
Internal organs involvement
K Scherer, AJ Bircher, Med Clin N Am 94 (2010) 681–689
• Sudden onset of unexplained high fever (>39OC)
• Disseminated lymphadenopathy
• Arthralgias, and arthritides
• Hepatopathy
• Nephropathy
• Pneumonitis
• Abnormal laboratory:
• Eosinophilia
• Activated (atypical) lymphocytes
• Cytopenia
![Page 67: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/67.jpg)
Clinical syndrome diagnosis
Bircher A. and Scherer K. Med Clin N Am 94 (2010) 711–725
Type I hypersensitivity Type II & III hypersensitivity Type IV hypersensitivity
![Page 68: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/68.jpg)
Immediate types
Urticaria
Angioedema
Anaphylaxis
![Page 69: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/69.jpg)
Anaphylaxis diagnostic criteria
Sampson HA et al.. J Allergy Clin Immunol 2006;117: 391-7.
![Page 70: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/70.jpg)
Anaphylaxis diagnostic criteria One of these:
1) Acute onset of an illness (minutes to several hours)
• With involvement of the skin, mucosal tissues, or both
• e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula
• And >/= 1 of the following:
• Respiratory compromise
• e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia
• Reduced BP or associated symptoms of end-organ dysfunction
• e.g., hypotonia [collapse], syncope, incontinence
Sampson HA et al.. J Allergy Clin Immunol 2006;117: 391-7.
![Page 71: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/71.jpg)
Anaphylaxis diagnostic criteria One of these:
2) >/=2 of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
• Involvement of skin-mucosal tissue
• e.g., generalized hives, itch-flush, swollen lips-tongue-uvula
• Respiratory compromise
• e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia
• Reduced BP or associated symptoms of end-organ dysfunction
• e.g., hypotonia [collapse], syncope, incontinence
• Persistent gastrointestinal symptoms
• e.g., crampy abdominal pain, vomiting
Sampson HA et al.. J Allergy Clin Immunol 2006;117: 391-7.
![Page 72: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/72.jpg)
Anaphylaxis: Diagnostic criteria One of these:
3) Reduced BP after exposure to known allergen for that patient (minutes to several hours):
• Infants and children:
• Low systolic BP (age specific) or greater than 30% decrease in systolic BP*
• Adults:
• Systolic BP less than 90 mm Hg or greater than 30% decrease from their baseline
Sampson HA et al.. J Allergy Clin Immunol 2006;117: 391-7.
![Page 73: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/73.jpg)
Delayed types
• Exanthematic manifestations
• Macular/maculopapular/papular exanthem
• Symmetrical drug-related intertriginous flexural exanthema (SDRIFE, former Baboon syndrome)
• Acute generalized exanthematous pustulosis (AGEP)
• Drug rash with eosinophilia and systemic symptoms
(DRESS)/drug hypersensitivity syndrome (DHS)
• Severe cutaneous adverse reactions (SCAR)
• Erythema multiforme (EM)
• Stevens–Johnson Syndrome (SJS)
• Toxic epidermal necrolysis (TEN)
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
![Page 74: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/74.jpg)
Delayed types
• Dermatitis
• Fixed drug eruption
• Others
• Cutaneous vasculitis
• Autoimmune skin disorders, for example drug-induced pemphigus or pemphigoid
• Stomatitis
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
![Page 75: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/75.jpg)
Delayed types
• Internal organ manifestations (isolated or in the context of complex exanthems)
• General symptoms: malaise, eosinophilia, fever, arthritis, lymphadenopathy
• Organ involvement: hepatitis, pneumonitis, nephritis, nephrotic syndrome, myocarditis
• Blood cell dyscrasias: neutropenia, thrombocytopenia, anemia
• Systemic vasculitis
• Systemic autoimmune disorders, for example drug-induced lupus erythematosus
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
![Page 76: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/76.jpg)
AGEP: Diagnostic scoring system
A. Sidoroff., et al., J Cutan Pathol 2001; 28: 113–119.
![Page 77: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/77.jpg)
DRESS: Diagnostic criteria (RegiSCAR)
Kardaun SH, et al. Response Br J Dermatol 2007; 156: 609–10.
• Hospitalization
• Reaction suspected to be drug-related
• Acute rash
• Fever > 38 OC*
• Enlarged lymph nodes at a minimum of 2 sites*
• Involvement of at least one internal organ*
• Blood count abnormalities*
• Lymphocytes above or below normal limits
• Eosinophils above the laboratory limits
• Platelets below the laboratory limits
• *3 of these 4 criteria are required for diagnosis
![Page 78: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/78.jpg)
DRESS: Diagnostic validation score
Kardaun SH, et al. Response Br J Dermatol 2007; 156: 609–10.
![Page 79: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/79.jpg)
DRESS/DiHS: Diagnostic criteria
Shiohara T, et al.. Br J Dermatol 2007; 156: 1045–92.
• MP rash developing > 3 wk after starting of the suspected drug
• Prolonged clinical symptoms 2 weeks after drug discontinuation
• Fever (> 38 OC)
• Liver abnormalities (ALT > 100 U ⁄ L)*
• Leucocyte abnormalities
• Leucocytosis (> 11 x 109 ⁄ L)
• Atypical lymphocytosis (> 5%)
• Eosinophilia (> 1.5 x 109 ⁄ L)
• Lymphadenopathy
• Human herpesvirus 6 reactivation
• Dx: 7 criteria = typical DIHS, first 5 criteria = atypical DIHS
• *This can be replaced by other organ involvement such as renal involvement.
![Page 80: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/80.jpg)
DRESS: Diagnostic criteria
ศรีศุภลักษณ์ สงิคาลวณิช, และคณะ, แนวทางการดูแลรักษากลุ่มอาการ Drug hypersensitivity syndrome
Bocquet H, et al.,. Semin Cutan Med Surg 1996;1:250–7.
อาศัยเกณฑก์ารวนิจิฉัยทัง้ 3 ขอ้ ดังตอ่ไปนี้
1. อาการแสดงทางผวิหนัง สว่นใหญ่เป็นผืน่แดงราบ (macule/ patch) หรอืนูน (papule/ plaque) แตอ่าจพบตุม่น ้าหรอืเป็นตุม่หนองได ้
2. CBC พบ eosinophil >/= 1,500 เซลล/์ลบ.มม. หรอืพบ atypical lymphocyte
3. มอีาการตามระบบตา่งๆ อยา่งนอ้ย 1 อาการไดแ้ก ่
a. ตอ่มน ้าเหลอืงโต >2 ซม.
b. ตับอักเสบ โดยพบมรีะดับเอนไซม ์transaminase >/= 2 เทา่
c. Interstitial nephropathy
d. Interstitial lung disease
e. Myocardial involvement
ในกรณีทีม่ปีระวัตกิารใชย้าทีม่คีวามเสีย่งสงูตอ่การเกดิ DHS/DRESS แมพ้บเกณฑก์าร วนิจิฉัยเพยีงขอ้ 1 และขอ้ 3 ก็สมควรหยุดยาและใหก้ารรักษา
![Page 81: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/81.jpg)
DRESS/DiHS: Dx criteria comparison
Z Husain, et al., J Am Acad Dermatol 2013;68:693.e1-14.
![Page 82: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/82.jpg)
SJS/TEN
M Mockenhaupt, Seminars in Cutaneous Medicine and Surgery, Vol. 33, March 2014, 10-16
• No consensus diagnostic criteria
• But there is severity classification system
![Page 83: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/83.jpg)
SJS/TEN
M Mockenhaupt, Seminars in Cutaneous Medicine and Surgery, Vol. 33, March 2014, 10-16
• And there is a mortality risk score: The SCORTEN
![Page 84: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/84.jpg)
SJS/TEN: The SCORTEN
S Bansal, et al., International Journal of Dermatology 2015, 54, e18–e26
Left: Serial analysis is better performed only on day 1
Right: Mortality is underestimated for scores of 2 and 3, and overestimated for scores of 4 and 5
![Page 85: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/85.jpg)
Consolidation of possible culprit
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Narrow candidate list by focusing on the following.
• Temporal association between drug starts and stops and onset
• Intensification and waning of signs and symptoms of reactions
• Consider pharmaco-epidemiology of the candidate list, and rank candidates by allergenic potential from published data
![Page 86: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/86.jpg)
Tools for culprit drug identification
DJ Doherty, Respiratory Medicine CME 2 (2009) 63–67
• A number of algorithms or decision aids have been published
• Jones’ algorithm
• Naranjo algorithm -> More commonly used
• Yale algorithm
• Karch algorithm
• Begaud algorithm
• The ADRAC
• WHO-UMC
• Quantitative approach algorithm
![Page 87: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/87.jpg)
Tools for culprit drug identification
Naranjo CA, et al. Clin. Pharmacol. Ther. (1981). 30 (2): 239–45.
• The Naranjo adverse drug reaction probability scale
• Interpretration: >9 = definite ADR, 5-8 = probable ADR, 1-4 = possible ADR, 0 = doubtful ADR
• The Naranjo criteria do not take into account drug-drug interactions.
Questions Yes No Unknown 1. Are there previous conclusive reports on this reaction? 2. Did the adverse event occur after the suspected drug was administered? 3. Did the adverse reaction improve when the drug was discontinued or a specific
antagonist was administered? 4. Did the adverse reaction reappear when the drug was re-administered? 5. Are there alternative causes (other than the drug) that could caused the reaction? 6. Did the reaction reappear when a placebo was given? 7. Was the drug detected in the blood (or other fluids) in toxic-level concentrations? 8. Was the reaction more severe with higher dose or less severe with lower dose? 9. Did the patient have similar reaction to the same or similar drugs previously? 10. Was the adverse event confirmed by any objective evidence?
+1 +2 +1 +2 -1 -1 +1 +1 +1 +1
0 -1 0 -1 +2 +1 0 0 0 0
0 0 0 0 0 0 0 0 0 0
![Page 88: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/88.jpg)
Tools for culprit drug identification
B Sassolas, et al., Clin Pharmacol Ther. 2010 Jul;88(1):60-8.
• For SJS/TEN: ALDEN (algorithm of drug causality for epidermal necrolysis) score
![Page 89: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/89.jpg)
Tools for culprit drug identification
B Sassolas, et al., Clin Pharmacol Ther. 2010 Jul;88(1):60-8.
• For SJS/TEN: ALDEN (algorithm of drug causality for epidermal necrolysis) scoer
![Page 90: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/90.jpg)
Intevention/investigation
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Stop and/or substitute all candidate drugs with good temporal relationship to syndrome and known allergic potential.
• Observe consequences of stopping medications.
• Consider skin testing if suspected drug is clinically imperative to assess IgE response.
• Disregard negative results within 28 days of acute anaphylaxis (i.e., false negative), and for all haptenic drugs without validated negative predictive value.
• Laboratory investigations (in-vitro tests)?
![Page 91: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/91.jpg)
Diagnosis and management
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Readminister incriminated drugs as clinically indicated.
• Use gradual dose escalation if skin test negative
• Use desensitization protocol if reaction IgE dependent or skin test positive
![Page 92: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/92.jpg)
Management algorithm (General)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 93: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/93.jpg)
Management algorithm (General)
P. Demoly, et al., International Consensus on drug allergy. Allergy 2014; 69: 420–437.
![Page 94: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/94.jpg)
Management algorithm (General)
P. Demoly, et al., International Consensus on drug allergy. Allergy 2014; 69: 420–437.
*Currently available biological tests lack sensitivity.
**In the absence of contraindications (In next slide)
***If no alternative is available (e.g., NMBA, chemotherapeutic drugs), readministration of the drug is allowed under close surveillance,considering premedication and/or desensitization.
![Page 95: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/95.jpg)
Management algorithm (General)
P. Demoly, et al., International Consensus on drug allergy. Allergy 2014; 69: 420–437.
Precautions and contraindications of performing DPTs
• 1 Noncontrollable and/or severe life-threatening DHRs:
• Severe cutaneous reactions (SJS, TEN, DRESS, vasculitis, AGEP)
• Systemic reactions eg.DRESS, any internal organ involvement, hematological reactions
• Anaphylaxis may be tested after risk/benefit analysis
• 2 DPTs are not indicated when:
• The offending drug is unlikely to be needed and several alternatives exist
• Severe concurrent illness or pregnancy (unless the drug is essential for the concurrent illness or required during pregnancy or delivery)
• 3 DPTs should be performed under the highest safety conditions:
• Trained staff: aware of the tests, ready to identify early signs of a positive reaction, and ready to manage a life-threatening reaction
• With emergency resuscitative equipment available
![Page 96: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/96.jpg)
Management algorithm (Specific)
Romano A. and Caubet J. J Allergy Clin Immunol Pract 2014;2:3-12
Beta lactam antibiotics (immediate reactions)
![Page 97: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/97.jpg)
Management algorithm (Specific)
Romano A. and Caubet J. J Allergy Clin Immunol Pract 2014;2:3-12
Beta lactam antibiotics (nonimmediate reactions)
![Page 98: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/98.jpg)
Management algorithm (Specific)
Romano A. and Caubet J. J Allergy Clin Immunol Pract 2014;2:3-12
Non-beta lactam antibiotics
![Page 99: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/99.jpg)
Management algorithm (Specific)
Adapted from M. L. Kowalski., et al., Position paper, Allergy 2013; 68: 1219–1232.
Latest classification of NSAID hypersensitivity reactions
![Page 100: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/100.jpg)
Management algorithm (Specific)
M. L. Kowalski., et al., Position paper, Allergy 2013; 68: 1219–1232.
NSAIDs (Acute form of reaction)
![Page 101: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/101.jpg)
Skin tests for drug allergy
K. Brockow, et al,. an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702–712.
![Page 102: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/102.jpg)
Skin tests for drug allergy
K. Brockow, et al,. an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702–712.
![Page 103: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/103.jpg)
Skin tests for drug allergy
K. Brockow, et al,. an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702–712.
![Page 104: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/104.jpg)
Skin tests for drug allergy
M. L. Kowalski., et al., Position paper, Allergy 2013; 68: 1219–1232.
NSAIDs (Delayed reaction)
![Page 105: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/105.jpg)
Skin tests for drug allergy
K. Brockow, et al,. an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702–712.
Drugs that value of skin tests has not adequately been demonstrated
• Antihypertensive drugs
• Biologicals other than anti-TNF preparations and omalizumab
• Hormones, corticosteroids and insulins
• Nonbetalactam antibiotics
• Nonplatinum chemotherapeutics
• NSAIDs other than pyrazolones for immediate reactions
• Opioids
• Sera, immunoglobulins and vaccines
![Page 106: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/106.jpg)
Provocative tests (gradual dose escalation)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Very few subjects with a positive history have positive drug challenge results
• Provocative drug tests should be implemented only…
• After consideration of risk-benefit ratio for each patient
• Performed by experienced personnel in an appropriate setting
• Informed consent can be obtained from the patient before the procedure
Lammintausta K, Kortekangas-Savolainen O. Acta Derm Venereol 2005;85:491-6.
![Page 107: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/107.jpg)
Provocative tests (gradual dose escalation)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
• Relatively contraindicated in
• Patients with Hx of TEN, SJS, DRESS, DiHS, AGEP, or severe organ-specific involvements.
• Do not perform if:
• An acute reaction occurred within the last 4-weeks
• Antihistamines or oral steroids are being used
• There are active signs of U/D
• Urticaria, uncontrolled asthma, or uncontrolled cardiac, renal, or hepatic disease or current upper airway infection.
• For IgE-dependent reactions, the principal concern is anaphylaxis, and lower initial doses are warranted.
Aberer W, et al. European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Allergy 2003;58:854-63.
![Page 108: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/108.jpg)
Provocative tests (gradual dose escalation)
M. L. Kowalski., et al., Position paper, Allergy 2013; 68: 1219–1232.
NSAIDs (acute reaction)
![Page 109: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/109.jpg)
Provocative tests (gradual dose escalation)
Nizankowska-Mogilnicka et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007;62:1111-8.
Single-blinded 3-days NSAIDs oral challenge protocol for AERD
The Lysine-ASA Bronchoprovocation Test Protocol
Berges-Gimeno M, et al. Ann Allergy Asthma Immunol 2002;89:474-8.
![Page 110: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/110.jpg)
Provocative tests (gradual dose escalation)
A White, et al., Ann Allergy Asthma Immunol. 2006;97:190–195.
Nasal ketorolac challenge
![Page 111: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/111.jpg)
Provocative tests (gradual dose escalation)
RU Lee, et al., Ann Allergy Asthma Immunol. 2010;105:130 –135.
Comparison of standard oral ASA and modified nasal ketorolac challenge
![Page 112: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/112.jpg)
Provocative tests (gradual dose escalation)
M. L. Kowalski., et al., Position paper, Allergy 2013; 68: 1219–1232.
NSAIDs (Dalayed reaction)
![Page 113: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/113.jpg)
Drug desensitization in IgE-type reaction
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Procedure
• Obtain a skin test to determine the patient’s degree of sensitivity (if available).
• Dilute available drug solution or suspension to 1-3 mg/mL.
• Prepare three tenfold dilutions.
• Perform prick or puncture testing with a 1 : 1000 dilution.
• If the result is negative, perform serial intradermal tests, using 0.02 mL (3- to 4-mm bleb) in duplicate, up to and including 3 mg/mL stock; discontinue testing when >8 mm wheal is observed.
• Positive result = both duplicate wheals increase significantly (>2-3 mm) 20 minutes after placement compared with diluent control.
• Prepare sufficient quantities of drug solution or suspension for desensitization regimen in 10x dilutions from full therapeutic dose
![Page 114: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/114.jpg)
Drug desensitization in IgE-type reaction
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Preparation
• Establish baseline monitoring in a medical setting appropriate for patient’s clinical conditions and the nature or severity of prior reaction.
• Start a secure intravenous infusion.
• Starting dose:
• If the skin test result negative and the test is unvalidated, begin with 0.1 mL of a 1:100 dilution (start with a 1:1000 dilution in severe reactions)
• If the skin test result is positive, begin 100-fold below dose that produces midpoint reaction (5- to 8-mm wheal).
![Page 115: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/115.jpg)
Drug desensitization in IgE-type reaction
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Preparation
• Route:
• Oral by ingestion or nasogastric tube in 30 mL of water
• Parenteral by intradermal (<0.2 mL)
• Subcutaneous (0.2-0.6 mL)
• Intramuscular (>0.6 mL) injection
• Dosing interval
• 15-20 minutes for parenteral doses
• 20-30 minutes for oral dosing
• Repeat dose for mild to moderate systemic reactions
• Drop back 2 doses for any reaction causing hemodynamic changes
• Dose escalation: 2x increments
![Page 116: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/116.jpg)
Drug desensitization in IgE-type reaction
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Follow up
• If iv therapy follows desensitization, continuous 24-hour drug infusion is preferable if feasible.
• If not, avoid rapid infusion of intermittent drug doses.
• If drug skin test result was positive, repeat after desensitization to document shift in skin sensitivity.
• Avoid lapses in therapeutic doses.
• Treat through selected mild to moderate reactions (e.g., urticaria) to avoid need to repeat desensitization.
• Before subsequent courses of therapy, repeat desensitization if skin test results remain positive
• Desensitization therapy is dose and drug dependent.
![Page 117: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/117.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Criteria for desensitization
• Drug therapy is essential
• Drug is irreplaceable, more effective than alternatives, or it has a unique mechanism
• Unavailability of a non-cross-reacting drug
• Previous reaction is well documented and not severe, preferably, the mechanism is known after allergologic workup
• Potential benefits outweigh the potential risks
![Page 118: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/118.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Absolute contraindications of drug desensitization
• Severe or life-threatening drug-induced diseases
• Such as SJS/TEN, DHS/DIHS/DRESS, cutaneous or systemic vasculitis, severe mucosal ulcerations
• Drug-induced autoimmune disorders
• Drug-induced severe general symptoms
• Such as drug fever, arthritis, generalized lymphadenopathy
• Drug-induced organ involvement
• Such as hepatitis, nephritis, pneumonitis, or cytopenias, or severe eosinophilia
![Page 119: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/119.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Relative contraindications of drug desensitization
• AGEP
• Underlying autoimmune disorders
• Pre-existing severe renal or hepatic impairment
• Severe cardiac disease/hemodynamically unstable patient
• Simultaneous treatment with potentially interfering drugs
![Page 120: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/120.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Recommendation
• Things to consider before start
• Characterize patient
• Check criteria and contraindications
• Assess clinical manifestation of previous reaction as detailed as possible
• Possibly on the basis of allergological tests
• Possibly confirm diagnosis by provocation tests
• Affirm comorbidities, comedications, and risk factors
• Obtain written informed consent
![Page 121: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/121.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Recommendation
• Choose appropriate protocol
• Check whether protocol for the culprit drug exists
• Check for clinical description of patients, soundness of the protocol, and success rate/outcome
• If there exists, no appropriate protocol check below
![Page 122: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/122.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Recommendation
• Prior to starting the procedure
• Assess complete clinical status
• Document skin, mucous membranes, internal organs, lymph nodes
• Laboratory as appropriate, but at least CBC, LFT, BUN/Cr, CRP
• Decide on starting dose, dose increments, and dose intervals
![Page 123: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/123.jpg)
Drug desensitization in delayed reaction
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Recommendation
• During and after desensitization
• Apply chosen protocol, modify according to criteria below
• Check skin and mucous membranes, lymph nodes, body temperature, at regular intervals
• Recommended at least daily
• Laboratory parameters as appropriate
• Monitor the underlying disease appropriately
• In case of an adverse event:
• Adjust the protocol or stop the procedure
• Administer symptomatic treatment
![Page 124: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/124.jpg)
Drug desensitization protocols
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Beta lactam antibiotic
![Page 125: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/125.jpg)
Drug desensitization protocols
K. Scherer , et al., an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844–852.
Non-beta lactam antibiotic
![Page 126: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/126.jpg)
Prediction of high-risk population
![Page 127: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/127.jpg)
Who is at risk?
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
![Page 128: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/128.jpg)
Why they are at risk?
![Page 129: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/129.jpg)
Why they are at risk?
![Page 130: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/130.jpg)
Why they are at risk?
![Page 131: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/131.jpg)
Why they are at risk?
![Page 132: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/132.jpg)
Finding genetic factors of ADRs
• Study of the affects of genetic factors on the inconsistency of drug response by assessing the extent of the contribution of variant forms of human genes to the observed variability in drug disposition, drug action or drug toxicity
• Goal: to identify the right dose of the right drug for a given individual
• Typically, genotyping or phenotyping strategies focus on a single gene
Pharmacogenetics
JS Leeder, Drug Discovery Today, Vol. 9, No. 13 July 2004, page 567-573
![Page 133: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/133.jpg)
Finding genetic factors of ADRs
• Investigations use constantly emerging and evolving genomic technologies to encompass comprehensive, genome-wide strategies targeted at identifying all factors that influence the response of a patient to small molecules that have been administered with therapeutic intent.
• Goal: To identifying (developing) the right drug for a given disease in the context of complex genomic factors.
Pharmacogenomics
JS Leeder, Drug Discovery Today, Vol. 9, No. 13 July 2004, page 567-573
![Page 134: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/134.jpg)
Example of current knowledge
SC Su, et al., Biomed Res Int. 2014;2014:824343.
![Page 135: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/135.jpg)
Example of current knowledge
SC Su, et al., Biomed Res Int. 2014;2014:824343.
![Page 136: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/136.jpg)
Example of current knowledge
Chonlaphat Sukasem, et al., Asian Pac J Allergy Immunol 2014;32:111-23
![Page 137: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/137.jpg)
Example of current knowledge
Chonlaphat Sukasem, et al., Asian Pac J Allergy Immunol 2014;32:111-23
![Page 138: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/138.jpg)
More diagnostic tools should be made available
![Page 139: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/139.jpg)
What else? (Apart from skin/provocative tests)
S Bansal, et al., International Journal of Dermatology 2015, 54, e18–e26
Better validation algorithm/scoring systems
![Page 140: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/140.jpg)
What else? (Apart from skin/provocative tests)
S Bansal, et al., International Journal of Dermatology 2015, 54, e18–e26
Better validation algorithm/scoring systems
![Page 141: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/141.jpg)
What else? (Apart from skin/provocative tests)
S Bansal, et al., International Journal of Dermatology 2015, 54, e18–e26
Better validation algorithm/scoring systems
![Page 142: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/142.jpg)
What else? (Apart from skin/provocative tests)
Blanca M, et al. Allergy 2001;56:862-70.
Fontaine C, Mayorga C, Bousquet PJ, et al. Allergy 2007; 62:47-52.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Laboratory (in-vitro) tests
• For immediate reactions
• Solid-phase immunoassays for specific IgE
• Only with penicillin allergy have in vitro test results been systematically compared with those of skin tests
• Sensitivity for penicilloyl-IgE
• 65-85% compared with PPL skin tests
• 32-50% compared with skin test+provocative test
• Minor determinant penicillin IgE antibodies are not reliably detected by available allergosorbent-type immunoassays.
![Page 143: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/143.jpg)
What else? (Apart from skin/provocative tests)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Laboratory (in-vitro) tests
• For immediate reactions
• Solid-phase immunoassays for specific IgE
• Immunoassays for documenting IgE antibodies to quinolone antibiotics, rocuronium, and other drugs have been reported, but their validity is unknown.
![Page 144: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/144.jpg)
What else? (Apart from skin/provocative tests)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Laboratory (in-vitro) tests
• For immediate reactions
• Flow cytometry to detect drug-induced basophil activation by means of increased surface markers such as CD63 and CD203c
• Cysteinyl leukotrienes released from blood leukocytes after drug incubation
These tests remain investigational.
![Page 145: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/145.jpg)
What else? (Apart from skin/provocative tests)
Szebeni J. Crit Rev Ther Drug Carrier Syst 2001;18:567-606.
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Laboratory (in-vitro) tests
• For delayed reactions
• Lymphocyte transformation tests (LTT)
• Positive in 78% of patients classified as highly likely to be drug allergic on clinical grounds
• Overall specificity was 85%
• False-positive results were observed, especially with NSAIDs.
• Flow cytometric lymphocyte activation test (LAT)
• T cell assays eg. drug-stimulated cytokines such as IL-5, IFN-γ, and IL-2
![Page 146: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/146.jpg)
What else? (Apart from skin/provocative tests)
Celik G., et al. Middleton’s Allergy 8th edition, 2013,1274-1295
Laboratory (in-vitro) tests
• For delayed reactions
• Immunoassays for IgG, IgM, or IgA responses to drug allergens not useful.
• CH50, C3 and C4 levels are useful indicators of the presence and severity of complement activation in immune complex disorders such as serum sickness syndromes
• Diagnostic utility of anaphylatoxin measurements (C3a, C4a, and C5a) remains to be defined
![Page 147: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/147.jpg)
![Page 148: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/148.jpg)
• Drug hypersensitivity reactions (DHRs) is one of major problem in modern medicine
• DHRs can mediated by both immunologic and non-immunologic mechanism and multiple mechanisms can concurrently occur at the same time
• Clinical presentations of DHRs have high heterogeniety. To make a diagnosis and identify the culprit drug needs multiple aspects to consider. Currently, only in-vivo tests are validated for some drugs
• Prervention of DHRs might include genetic screening
• Management must be individualized and based on risk vs benefit judgement.
• If drug provocation or desensitization is chosen, the procedure must be run at maximal available safety measures.
![Page 149: Drug allergy: Principles and Updates](https://reader030.vdocuments.mx/reader030/viewer/2022032615/55a287e21a28abe0748b45a5/html5/thumbnails/149.jpg)